

WEST Search History

DATE: Tuesday, February 21, 2006

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L9	(lactobionate? erythromycin? CTFA) same (insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L8	(lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L7	(lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (Insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L6	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (Insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L5	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (stor\$ preserv\$) same (Insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L4	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (stor\$ preserv\$) with organ	0
<input type="checkbox"/>	L3	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (stor\$ preserv\$)	80
<input type="checkbox"/>	L2	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA)	754
<input type="checkbox"/>	L1	6172185.pn.	1

END OF SEARCH HISTORY

WEST Search History

DATE: Tuesday, February 21, 2006

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
	<i>DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L22	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (composition formulation solution agent?) same (stor\$ preserv\$) with (organ\$ tissue?) and (insulin with like growth factor I or IGF-1)	34
<input type="checkbox"/>	L21	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (composition formulation solution agent?) same (stor\$ preserv\$) with organ\$ same (insulin with like growth factor I or IGF-1)	3
<input type="checkbox"/>	L20	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (composition formulation solution agent?) same (stor\$ preserv\$) with organ\$ same (lactobionate? erythromycin)	6
<input type="checkbox"/>	L19	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (composition formulation solution agent?) same (stor\$ preserv\$) with organ\$	1034
<input type="checkbox"/>	L18	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (composition formulation solution agent?) same (stor\$ preserv\$)	21104
<input type="checkbox"/>	L17	(L12 or L13) and insulin and antimicrob\$ and (preserv\$ or stor\$)	3
<input type="checkbox"/>	L16	L10 and insulin and antimicrob\$	2
<input type="checkbox"/>	L15	L10 and insulin	2
<input type="checkbox"/>	L14	L10 and insulin	1
<input type="checkbox"/>	L13	6630197.pn. or 6696238.pn.	2
<input type="checkbox"/>	L12	6503881.pn. or 6946261.pn.	2
<input type="checkbox"/>	L11	6503881.pn.L10	0
<input type="checkbox"/>	L10	6172185.pn. or 6849714.pn. or 6887470.pn.	3
<input type="checkbox"/>	L9	(lactobionate? erythromycin? CTFA) same (insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L8	(lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L7	(lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (Insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L6	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (Insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L5	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (stor\$ preserv\$) same (Insulin with like growth factor I or IGF-1)	0
<input type="checkbox"/>	L4	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (stor\$ preserv\$) with organ	0
<input type="checkbox"/>	L3	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA) same (composition formulation solution agent?) same (stor\$ preserv\$)	80
<input type="checkbox"/>	L2	(antibiotic\$ antimicrobi\$3 antibacteri\$3) same (lactobionate? erythromycin? CTFA)	754

FILE 'HOME' ENTERED AT 16:17:29 ON 21 FEB 2006

=> index chemistry bioscience medicine
FILE 'ENCOMPLIT2' ACCESS NOT AUTHORIZED
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUALINE, AQUIRE, BABS, BIOTECHNO,
CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CERAB, CIN, COMPENDEX, CONFSCI,
COPPERLIT, CORROSION, DISSABS, ENCOMPLIT, FEDRIP, GENBANK, INSPEC,
INSPHYS, INVESTEXT, IPA, JICST-EPLUS, ...' ENTERED AT 16:18:25 ON 21 FEB 2006

95 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (antibiotic? or antimicrobi? or antibacteri?) (P)(stor? or preserv?) (S) organ? and
(lactobionate? or erythromycin) and (insulin (A) like growth factor 1 or IGF-1)

- 0* FILE ALUMINIUM
- 0* FILE APOLLIT
- 0* FILE AQUALINE
- 0* FILE BABS
- 0* FILE BIOTECHNO

8 FILES SEARCHED...

- 0* FILE CAOLD
- 0* FILE CBNB
- 0* FILE CEABA-VTB
- 0* FILE CIN
- 0* FILE COMPENDEX

16 FILES SEARCHED...

- 0* FILE COPPERLIT
- 0* FILE CORROSION
- 0* FILE ENCOMPLIT
- 0* FILE FEDRIP
- 0* FILE INSPEC

24 FILES SEARCHED...

- 0* FILE INSPHYS
- 0* FILE KOSMET
- 0* FILE METADEX
- 0* FILE NTIS

33 FILES SEARCHED...

- 0* FILE PASCAL

35 FILES SEARCHED...

- 0* FILE RAPRA
- 0* FILE WATER
- 0* FILE WELDASEARCH

44 FILES SEARCHED...

- 0* FILE WSCA
- 0* FILE ADISNEWS
- 0* FILE ANTE
- 0* FILE BIOENG

52 FILES SEARCHED...

- 1* FILE BIOTECHABS
- 1* FILE BIOTECHDS

59 FILES SEARCHED...

- 0* FILE ESBIODASE

65 FILES SEARCHED...

- 0* FILE FOMAD
- 0* FILE FOREGE
- 0* FILE FROSTI
- 0* FILE FSTA
- 3 FILE IFIPAT

76 FILES SEARCHED...

- 0* FILE NUTRACEUT
- 0* FILE PHARMAML
- 10 FILE USPATFULL

88 FILES SEARCHED...
2 FILE USPAT2
1 FILE WPIDS
92 FILES SEARCHED...
1 FILE WPINDEX
94 FILES SEARCHED...

7 FILES HAVE ONE OR MORE ANSWERS, 95 FILES SEARCHED IN STNINDEX

L1 QUE (ANTIBIOTIC? OR ANTIMICROBI? OR ANTIBACTERI?) (P) (STOR? OR PRESERV?)
(S) ORGAN? AND (LACTOBIONATE? OR ERYTHROMYCIN) AND (INSULIN (A) LIKE G
ROWTH FACTOR 1 OR IGF-1)

=> D rank

F1	10	USPATFULL
F2	3	IFIPAT
F3	2	USPAT2
F4	1	WPIDS
F5	1	WPINDEX
F6	1*	BIOTECHABS
F7	1*	BIOTECHDS

=> FIL F1-5

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.98	11.40

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 16:29:23 ON 21 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 16:29:23 ON 21 FEB 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPAT2' ENTERED AT 16:29:23 ON 21 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:29:23 ON 21 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S L1

L2	10	FILE USPATFULL
L3	3	FILE IFIPAT
L4	2	FILE USPAT2
L5	1	FILE WPIDS

TOTAL FOR ALL FILES

L6 16 L1

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 12 DUP REM L6 (4 DUPLICATES REMOVED)

=> D L7 1-12 ibib abs

L7 ANSWER 1 OF 12 USPATFULL on STN DUPLICATE 1
ACCESSION NUMBER: 2005:104901 USPATFULL
TITLE: Transplant media
INVENTOR(S): Murphy, Christopher J., Madison, WI, UNITED STATES
McAnulty, Jonathan F., Oregon, WI, UNITED STATES
Reid, Ted W., Lubbock, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005089836	A1	20050428
APPLICATION INFO.:	US 2003-657851	A1	20030909 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-917340, filed on 27		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221632P	20000728 (60)
	US 2000-249602P	20001117 (60)
	US 2001-290932P	20010515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JOHN H CROZIER, 1934 HUNTINGTON TURNPIKE, TRUMBULL, CT, 06611, US	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1-52	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2914	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to media containing purified **antimicrobial** polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the **storage** and **preservation** of internal **organs** prior to transplant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 12 USPATFULL on STN
 ACCESSION NUMBER: 2005:260910 USPATFULL
 TITLE: Silver-containing compositions, devices, and methods for making
 INVENTOR(S): Gibbins, Bruce L., Lake Oswego, OR, UNITED STATES
 Hopman, Lance D., Tigard, OR, UNITED STATES
 PATENT ASSIGNEE(S): AcryMed, Inc., Portland, OR, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005226931	A1	20051013
APPLICATION INFO.:	US 2004-978556	A1	20041101 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-441275, filed on 19 May 2003, GRANTED, Pat. No. US 6897349 Continuation of Ser. No. US 2000-675892, filed on 29 Sep 2000, GRANTED, Pat. No. US 6605751 Continuation-in-part of Ser. No. US 1998-191223, filed on 13 Nov 1998, GRANTED, Pat. No. US 6355858 Continuation-in-part of Ser. No. US 1997-971074, filed on 14 Nov 1997, GRANTED, Pat. No. US 5928174		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212455P	20000619 (60)
	US 1999-157000P	19991001 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TROUTMAN SANDERS LLP, BANK OF AMERICA PLAZA, SUITE 5200, 600 PEACHTREE STREET , NE, ATLANTA, GA, 30308-2216, US	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2277	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises methods and compositions for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compositions for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2005:117724 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005100991	A1	20050512
APPLICATION INFO.:	US 2004-932104	A1	20040902 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-833118, filed on 12 Apr 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	15444		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 12 USPATFULL on STN

DUPLICATE 2

ACCESSION NUMBER: 2004:13692 USPATFULL
TITLE: Silver-containing compositions, devices and methods for making
INVENTOR(S): Gibbins, Bruce L., Lake Oswego, OR, UNITED STATES
Hopman, Lance D., Tigard, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010215	A1	20040115
	US 6897349	B2	20050524
APPLICATION INFO.:	US 2003-441275	A1	20030519 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-675892, filed on 29 Sep 2000, GRANTED, Pat. No. US 6605751 Continuation of Ser. No. US 1998-191223, filed on 13 Nov 1998, GRANTED, Pat. No. US 6355858 Continuation-in-part of Ser. No. US 1997-971074, filed on 14 Nov 1997, GRANTED, Pat. No. US 5928174		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212455P	20000619 (60)
	US 1999-157000P	19991001 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TROUTMAN SANDERS LLP, BANK OF AMERICA PLAZA, SUITE 5200, 600 PEACHTREE STREET , NE, ATLANTA, GA, 30308-2216	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2195	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises methods and compositions for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compositions for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2004:101731 USPATFULL
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene, Waltham, MA, UNITED STATES
Miller, Glenn T., Merrimac, MA, UNITED STATES
Jesson, Michael I., Hopedale, MA, UNITED STATES
Jones, Barry, Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S): Point Therapeutics, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004077601	A1	20040422
APPLICATION INFO.:	US 2003-616694	A1	20030709 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-394856P	20020709 (60)
	US 2002-414978P	20021001 (60)
	US 2003-466435P	20030428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	484	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	6519	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease. Compositions containing Ile-boroPro compounds are also provided. The invention embraces the use of these compounds alone or in combination with other therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 12 IFIPAT COPYRIGHT 2006 IFI on STN

AN 04024018 IFIPAT;IFIUDB;IFICDB
TITLE: TRANSPLANT MEDIA; USED FOR STORAGE AND PRESERVATION OF ORGANS PRIOR TO TRANSPLANT
INVENTOR(S): McAnulty; Jonathan F., 2822 Lalor Rd., Oregon, WI, 53575
Murphy; Christopher J., 1509 Wood La., Madison, WI, 53705
Reid; Ted W., 4501 82nd La., Lubbock, TX, 79424
PATENT ASSIGNEE(S): Unassigned
PRIMARY EXAMINER: Saucier, Sandra E
AGENT: Medlen & Carroll, LLP

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6696238	B2	20040224
	US 2002090369	A1	20020711
APPLICATION INFORMATION:	US 2001-917340		20010727
EXPIRATION DATE:	27 Jul 2021		

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 2000-221632P	20000728 (Provisional)
	US 2000-249602P	20001117 (Provisional)

FAMILY INFORMATION: US 2001-290932P 20010515 (Provisional)
US 6696238 20040224
DOCUMENT TYPE: US 2002090369 20020711
Utility
Granted Patent - Utility, with Pre-Grant Publication
FILE SEGMENT: CHEMICAL
GRANTED

PARENT CASE DATA:

This application claims priority to U.S. provisional application No. 60/221,632, filed Jul. 28, 2000, No. 60/249,602, filed Nov. 17, 2000, and No. 60/290,932, filed May 15, 2001.

NOTE: INDEXED FROM APPLICATION
NUMBER OF CLAIMS: 17
GRAPHICS INFORMATION: 9 Drawing Sheet(s), 9 Figure(s).
DESCRIPTION OF FIGURES:

FIG. 1 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for 3 days in UW solution alone (solid line) or in UW solution supplemented with BNP-1 (dashed line).

FIG. 2 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for four days in UW solution alone (solid circles), in UW solution supplemented with BNP-1 (solid squares), or in UW solution supplemented with BNP-1 and growth factors (x's).

FIG. 3 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for four days in UW solution alone (solid triangles) or six days in UW solution supplemented with trophic factors (unfilled triangles).

FIG. 4 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution alone (solid triangles) or six days in UW solution supplemented with trophic factors (squares).

FIG. 5 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution alone (squares) or five days in UW solution supplemented with trophic factors (circles).

FIG. 6 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution alone (squares) or four days in UW solution supplemented with trophic factors (diamonds).

FIG. 7 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for four days in UW solution alone (solid triangles) or four days in UW solution supplemented with trophic factors (diamonds).

FIG. 8 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for five days in UW solution with trophic factors and with starch (circles) or five days in UW solution supplemented with trophic factors and without starch (squares).

FIG. 9 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution supplemented with BNP-1 (L-form isomer) (circles) or three days in UW solution supplemented with BNP-1 (D-form isomer) (squares).

AB The present invention relates to media containing purified **antimicrobial** polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the **storage** and **preservation** of internal **organs** prior to transplant.

NTE INDEXED FROM APPLICATION

CLMN 17

GI 9 Drawing Sheet(s), 9 Figure(s).

FIG. 1 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for 3 days in UW solution alone (solid line) or in UW solution supplemented with BNP-1 (dashed line).

FIG. 2 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for four days in UW solution alone (solid circles), in UW solution supplemented with BNP-1 (solid squares), or in UW solution supplemented with BNP-1 and growth factors (x's).

FIG. 3 is a graph showing serum creatinine levels (Y-axis) over time

(X-axis) in dogs receiving kidneys stored for four days in UW solution alone (solid triangles) or six days in UW solution supplemented with trophic factors (unfilled triangles).

FIG. 4 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution alone (solid triangles) or six days in UW solution supplemented with trophic factors (squares).

FIG. 5 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution alone (squares) or five days in UW solution supplemented with trophic factors (circles).

FIG. 6 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution alone (squares) or four days in UW solution supplemented with trophic factors (diamonds).

FIG. 7 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for four days in UW solution alone (solid triangles) or four days in UW solution supplemented with trophic factors (diamonds).

FIG. 8 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for five days in UW solution with trophic factors and with starch (circles) or five days in UW solution supplemented with trophic factors and without starch (squares).

FIG. 9 is a graph showing serum creatinine levels (Y-axis) over time (X-axis) in dogs receiving kidneys stored for three days in UW solution supplemented with BNP-1 (L-form isomer) (circles) or three days in UW solution supplemented with BNP-1 (D-form isomer) (squares).

L7 ANSWER 7 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:258639 USPATFULL

TITLE: 207 human secreted proteins

INVENTOR(S):

Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Fan, Ping, Potomac, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING		

NUMBER	DATE
-----	-----

PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)
	US 1997-48880P	19970606 (60)
	US 1997-48896P	19970606 (60)
	US 1997-49020P	19970606 (60)
	US 1997-48876P	19970606 (60)
	US 1997-48895P	19970606 (60)
	US 1997-48884P	19970606 (60)
	US 1997-48894P	19970606 (60)
	US 1997-48971P	19970606 (60)
	US 1997-48964P	19970606 (60)
	US 1997-48882P	19970606 (60)
	US 1997-48899P	19970606 (60)
	US 1997-48893P	19970606 (60)
	US 1997-48900P	19970606 (60)
	US 1997-48901P	19970606 (60)
	US 1997-48892P	19970606 (60)
	US 1997-48915P	19970606 (60)
	US 1997-49019P	19970606 (60)
	US 1997-48970P	19970606 (60)
	US 1997-48972P	19970606 (60)
	US 1997-48916P	19970606 (60)
	US 1997-49373P	19970606 (60)
	US 1997-48875P	19970606 (60)
	US 1997-49374P	19970606 (60)
	US 1997-48917P	19970606 (60)
	US 1997-48949P	19970606 (60)
	US 1997-48974P	19970606 (60)
	US 1997-48883P	19970606 (60)
	US 1997-48897P	19970606 (60)
	US 1997-48898P	19970606 (60)
	US 1997-48962P	19970606 (60)
	US 1997-48963P	19970606 (60)
	US 1997-48877P	19970606 (60)
	US 1997-48878P	19970606 (60)
	US 1997-57645P	19970905 (60)
	US 1997-57642P	19970905 (60)
	US 1997-57668P	19970905 (60)
	US 1997-57635P	19970905 (60)
	US 1997-57627P	19970905 (60)
	US 1997-57667P	19970905 (60)
	US 1997-57666P	19970905 (60)
	US 1997-57764P	19970905 (60)
	US 1997-57643P	19970905 (60)
	US 1997-57769P	19970905 (60)
	US 1997-57763P	19970905 (60)
	US 1997-57650P	19970905 (60)
	US 1997-57584P	19970905 (60)
	US 1997-57647P	19970905 (60)
	US 1997-57661P	19970905 (60)
	US 1997-57662P	19970905 (60)
	US 1997-57646P	19970905 (60)
	US 1997-57654P	19970905 (60)
	US 1997-57651P	19970905 (60)
	US 1997-57644P	19970905 (60)
	US 1997-57765P	19970905 (60)
	US 1997-57762P	19970905 (60)
	US 1997-57775P	19970905 (60)
	US 1997-57648P	19970905 (60)
	US 1997-57774P	19970905 (60)
	US 1997-57649P	19970905 (60)
	US 1997-57770P	19970905 (60)
	US 1997-57771P	19970905 (60)
	US 1997-57761P	19970905 (60)
	US 1997-57760P	19970905 (60)
	US 1997-57776P	19970905 (60)

US 1997-57778P	19970905 (60)
US 1997-57629P	19970905 (60)
US 1997-57628P	19970905 (60)
US 1997-57777P	19970905 (60)
US 1997-57634P	19970905 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)
US 1997-70923P	19971218 (60)
US 1998-92921P	19980715 (60)
US 1998-94657P	19980730 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 10 Drawing Page(s)
 LINE COUNT: 32746

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:216243 USPATFULL
 TITLE: Silver-containing compositions, devices and methods for making
 INVENTOR(S): Gibbins, Bruce L., Lake Oswego, OR, United States
 Hopman, Lance D., Aloha, OR, United States
 PATENT ASSIGNEE(S): Acrymed, Portland, OR, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6605751	B1	20030812
APPLICATION INFO.:	US 2000-675892		20000929 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-191223, filed on 13 Nov 1998, now patented, Pat. No. US 6355858		
	Continuation-in-part of Ser. No. US 1997-971074, filed on 14 Nov 1997, now patented, Pat. No. US 5928174		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212455P	20000619 (60)
	US 1999-157000P	19991001 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Millin, Vincent
 ASSISTANT EXAMINER: Hamilton, Lalita M.
 LEGAL REPRESENTATIVE: Troutman Sanders LLP
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 12 Drawing Figure(s); 8 Drawing Page(s)
 LINE COUNT: 2204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises methods and compositions for making a silver-containing antimicrobial hydrophilic material. More particularly, the present invention comprises methods and compositions for stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent. The matrix may be formed into any desired shape for its desired uses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 12 USPATFULL on STN DUPLICATE 3
ACCESSION NUMBER: 2002:171622 USPATFULL
TITLE: Transplant media
INVENTOR(S): Murphy, Chistopher J., Madison, WI, UNITED STATES
McAnulty, Jonathan F., Oregon, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002090369	A1	20020711
	US 6696238	B2	20040224
APPLICATION INFO.:	US 2001-917340	A1	20010727 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221632P	20000728 (60)
	US 2000-249602P	20001117 (60)
	US 2001-290932P	20010515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MEDLEN & CARROLL, LLP, Suit 350, 101 Howard Street, San Francisco, CA, 94105	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2230	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to media containing purified **antimicrobial** polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the **storage** and **preservation** of internal **organs** prior to transplant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 12 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2002-268995 [31] WPIDS
DOC. NO. CPI: C2002-079786
TITLE: Media comprising **antimicrobial** polypeptides or pore forming agents and/or cell surface receptor binding compounds useful for the **storage** and **preservation** of **organs** prior to transplant.
DERWENT CLASS: A96 B04 D16 D22
INVENTOR(S): MCANULTY, J F; MURPHY, C J; REID, T W
PATENT ASSIGNEE(S): (MURP-I) MURPHY C J; (MCAN-I) MCANULTY J F; (REID-I) REID T W
COUNTRY COUNT: 96
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002009738	A1	20020207	(200231)*	EN	74
RW:	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW				
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW				
AU 2001079073	A	20020213	(200238)		
US 2002090369	A1	20020711	(200248)		
EP 1305040	A1	20030502	(200331)	EN	
R:	AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR				
US 6696238	B2	20040224	(200415)		
US 2005089836	A1	20050428	(200530)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002009738	A1	WO 2001-US23785	20010727
AU 2001079073	A	AU 2001-79073	20010727
US 2002090369	A1 Provisional	US 2000-221632P	20000728
	Provisional	US 2000-249602P	20001117
	Provisional	US 2001-290932P	20010515
		US 2001-917340	20010727
EP 1305040	A1	EP 2001-957315	20010727
		WO 2001-US23785	20010727
US 6696238	B2 Provisional	US 2000-221632P	20000728
	Provisional	US 2000-249602P	20001117
	Provisional	US 2001-290932P	20010515
		US 2001-917340	20010727
US 2005089836	A1 Provisional	US 2000-221632P	20000728
	Provisional	US 2000-249602P	20001117
	Provisional	US 2001-290932P	20010515
	Cont of	US 2001-917340	20010727
		US 2003-657851	20030909

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001079073	A Based on	WO 2002009738
EP 1305040	A1 Based on	WO 2002009738
US 2005089836	A1 Cont of	US 6696238

PRIORITY APPLN. INFO: US 2001-290932P 20010515; US 2000-221632P 20000728; US 2000-249602P 20001117; US 2001-917340 20010727; US 2003-657851 20030909

AN 2002-268995 [31] WPIDS

AB WO 200209738 A UPAB: 20020516

NOVELTY - New transplant compositions comprising **antimicrobial** polypeptides or pore forming agents and/or cell surface receptor binding compounds.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a composition (I) comprising a purified **antimicrobial** polypeptide and hydroxyethyl starch;

(2) a composition (II) comprising and **antimicrobial** polypeptide and an impermeant anion selected from **lactobionate** and gluconate;

(3) a composition (III) comprising a purified **antimicrobial** polypeptide and an ex vivo internal organ;

(4) a method (M1) comprising:

(a) providing:

(i) cellular material selected from internal organs, skin and gametes; and

(ii) a solution comprising a purified **antimicrobial** polypeptide;

(b) storing the cellular material in the solution comprising a purified **antimicrobial** peptide

(5) a composition (IV) comprising a cell surface receptor binding compound and hydroxyethyl starch;

(6) a kit comprising:

(a) a vessel containing a solution comprising a compound selected from **lactobionate** and hydroxyethyl starch; and

(b) a vessel containing an **antimicrobial** polypeptide;

(7) a process (P1) for producing a storage solution comprising:

(a) providing a solution comprising a compound selected from hydroxyethyl starch and **lactobionate** and a purified **antimicrobial** polypeptide; and

(b) combining the solution with the purified **antimicrobial** polypeptide to produce a storage solution; and

(8) a composition (V) comprising a purified **antimicrobial**

polypeptide and at least one purified cell surface receptor binding compound, for use as a supplement for **organs storage** solutions.

USE - The media is useful for **storing** and **preserving organs** e.g. kidneys, hearts and livers prior to transplant (claimed), and the **preservation** and **storage** of cellular materials in general.

ADVANTAGE - The media is capable of extending the **preservation** period past 72 hours and can provide **organs** with increased functionality upon transplant. animals receiving kidneys **stored** in the media of the present invention for either three or four days had serum creatinine levels of less than half of those observed in control animals receiving kidneys **stored** in UW solution (defined in the specification) alone. Lower serum creatinine levels are indicative of healthier kidneys and a more preferable prognosis for the transplant patient. It is contemplated that transplant of healthier **organs** leads to a decrease in chronic rejection.

Dwg.0/9

L7 ANSWER 11 OF 12 USPATFULL on STN

ACCESSION NUMBER: 1998:18805 USPATFULL

TITLE: Method of treatment of some resistant infections, cancer and other diseases which have infection and localized metal deposits in pathological areas

INVENTOR(S): Omura, Yoshiaki, 800 Riverside Dr. (8-I), New York, NY, United States 10032

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5720304		19980224
APPLICATION INFO.:	US 1996-609530		19960301 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Millin, Vincent		
ASSISTANT EXAMINER:	O'Hara, Kelly		
LEGAL REPRESENTATIVE:	Kane, Dalsimer, Sullivan, Kurucz, Levy, Eisele and Richard, LLP		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1783		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment of chlamydia trachomatis, Herpes family viral infections and other medical conditions through the removal of localized heavy metal (eg. Hg) and/or Al deposits and delivering antibiotics and/or antiviral agents along with the ingestion of greens taken from the Umbelliferae family of vegetables including leaves of Coriandrum Sativum known as cilantro or Chinese parsley coupled with drug intake enhancement methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 12 USPATFULL on STN

ACCESSION NUMBER: 94:15529 USPATFULL

TITLE: Cryogel oral pharmaceutical composition containing therapeutic agent

INVENTOR(S): Wood, Louis L., Rockville, MD, United States
Calton, Gary J., Elkridge, MD, United States

PATENT ASSIGNEE(S): SRCHEM Incorporated, Elkridge, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5288503		19940222
APPLICATION INFO.:	US 1992-899369		19920616 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-821627, filed on 16 Jan 1992, now patented, Pat. No. US 5260066		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Phelan, Gabrielle		

LEGAL REPRESENTATIVE: Ramsey, William S.

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1

LINE COUNT: 1265

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral pharmaceutical composition comprising a hydrophobic resin or ion exchange resin which has a therapeutic agent bound thereto forming an agent-resin complex is disclosed. The complex is coated with a wat